Feasibility and safety of surfactant administration via laryngeal mask airway as first-line therapy for a select newborn population: results of a standardized clinical protocol

期刊论文
发表日期：

2024年8月30日

查看全文

Zuzanna Kubicka,
Eyad Zahr,
Henry A. Feldman,
Tamara Rousseau,
Theresa Welgs,
Amy Ditzel,
Diana Perry,
Molly Lacy,
Carolyn O’Rourke,
Bonnie Arzuaga

摘要

Objectives

(1) To demonstrate feasibility and safety of surfactant administration via laryngeal mask airway (LMA) as a first-line therapy. (2) To measure treatment success, defined as avoidance of intubation/invasive mechanical ventilation, and determine if specific clinical variables could predict success/failure.

Study design

Observational cohort with eligible infants given surfactant using one type of LMA via standardized protocol. Data was captured prospectively followed by retrospective chart review.

Results

120 infants ≥1250 g and 28.3–41.1 weeks gestation were included. First-line LMA surfactant therapy was successful in 70% of the infants and those infants weaned to room air significantly quicker than infants requiring subsequent intubation/mechanical ventilation (p = 0.002 by 72 h, p = 0.001 by 96 h). Clinical variables assessed could not predict treatment success/failure. Complications were infrequent and did not differ between groups.

Conclusion

First-line LMA surfactant is feasible and safe for certain infants. Prediction of treatment success was not possible in our cohort.